News

Dr. Harold Edington gives an overview of Australia's public health campaign regarding UV safety, as well as the lessons Americans can take away from these measures.

Investigators uncovered that the primary driving motivator for indoor tanning had to do with aesthetic concerns, followed by the perception of psychological and physical benefits.

The port delivery system provides good visual outcomes for patients with nAMD despite presence of fluid in post-hoc analysis of Archway trial.

A post-hoc analysis of the GATHER1 trial suggests avacincaptad pegol reduced GA lesion growth across all distances from the foveal center point, when compared to sham.

Longer time to intravitreal aflibercept injection (>3 months) showed less visual improvement versus shorter time (<1 month).

Data suggest continued prescribing, not initial prescribing, is linked to opioid addiction risk among exposed family members.

Data show metformin was associated with reduced odds of developing AMD, with low to moderate doses having the greatest potential benefit.

Dr. Singh discusses the promise of durability with the agent and the potential for reducing the amount of patient visits, while preserving visual outcomes.

Analysis of patient-reported outcomes last flu season show an approximate 10% increased risk of mild vaccination reactions when receiving both a COVID-19 booster and flu shot instead of a lone booster dose.

Overall 70% of the patients in both PDS with ranibizumab and ranibizumab alone had almost no retinal thickness fluctuations.

The recommendations are for how stakeholders and policy makers should support improvements in managing atopic dermatitis to achieve better disease control and ultimately reducing the costs and burden on individuals, society, and the economy.

Overall, 61.8% of patients on their first biologic agent reported clinical remission.

The majority of cases do not require the modification of therapy because it does not negatively affect the course of COVID-19.

The phase 3 data presented at the ISTH 2022 Annual Congress show an 86% reduction of treated bleeds in patients with hemophilia A or B with inhibitors.

Bronchiectasis varies in presentation and appears to affect individuals from broad areas of the country. According to Dr. Patrick Flume, the task is to figure out what the best method of management is.

Real-world patients showed improvement in visual acuity and anatomic parameters, but are still at an early time point in TRUCKEE study.

Evidence of pegcetacoplan treatment effect observed in the distribution of patients across quartiles in both OAKS and DERBY.

Monthly or every other month intravitreal pegcetacoplan reported to be tolerated in DERBY and OAKS trials.

The best overall outcomes were attained in eyes without fluid and ellipsoid zone integrity preservation, investigators said.

An assessment of anti-VEGF dose regimen strategies concludes with little difference in outcomes among treatment arms at 2 years.

New phase 3 data indicates significant improvements in disease severity in children 1-11 years old with eosinophilic esophagitis.

The latest EUA, for two-dose NVX-CoV2373, introduces a protein-based adjuvant vaccine to the COVID-19 prevention market.

Previous literature indicated a higher prevalence of eczema in children who live in areas with hard water, but this association was not explored in adults until now.

The overall prevalence of NAFLD was 40.6%, with every NAFLD patient having a BMI of at least 25.

The topical therapy has been under investigation as a first-in-class therapy for this highly contagious skin condition.

A significant factor in treating sickle cell disease is the practice of shared decision-making, which gives the provider and patient a collaborative approach to disease management, according to Dr. Titilope Fasipe.

Buprenorphine has shown to be effective and has the potential for widespread use to address the opioid epidemic. A subset of individuals with OUD have been acquiring it without a prescription.

Dr. Karan Lal provides an overview of laser therapy for acne, and speaks on the "phenomenal" responses observed in patients with the first and only FDA approved laser treatment, AviClear.